Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Operating Margin: 2012-2025

Historic Operating Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to -907.37%.

  • Agios Pharmaceuticals' Operating Margin rose 23956.00% to -907.37% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,061.80%, marking a year-over-year increase of 17630.00%. This contributed to the annual value of -1,166.47% for FY2024, which is 29305.00% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Operating Margin of -907.37% as of Q3 2025, which was up 11.05% from -1,020.12% recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Operating Margin peaked at -907.37% during Q3 2025, and registered a low of -12,156.85% during Q1 2022.
  • Its 3-year average for Operating Margin is -1,244.15%, with a median of -1,221.97% in 2025.
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 1,054,136bps in 2023, then crashed by 9,763bps in 2025.
  • Agios Pharmaceuticals' Operating Margin (Quarterly) stood at -2,300.97% in 2022, then skyrocketed by 80,475bps to -1,496.23% in 2023, then skyrocketed by 33,092bps to -1,165.30% in 2024, then surged by 23,956bps to -907.37% in 2025.
  • Its Operating Margin was -907.37% in Q3 2025, compared to -1,020.12% in Q2 2025 and -1,221.97% in Q1 2025.